Benitec Biopharma (BNTC) Equity Average (2019 - 2025)
Historic Equity Average for Benitec Biopharma (BNTC) over the last 7 years, with Q1 2025 value amounting to $299.6 million.
- Benitec Biopharma's Equity Average rose 212155.36% to $299.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $299.6 million, marking a year-over-year increase of 212155.36%. This contributed to the annual value of $23.7 million for FY2024, which is 143858.63% up from last year.
- Per Benitec Biopharma's latest filing, its Equity Average stood at $299.6 million for Q1 2025, which was up 212155.36% from $172.8 million recorded in Q4 2024.
- Benitec Biopharma's 5-year Equity Average high stood at $299.6 million for Q1 2025, and its period low was $2.5 million during Q2 2023.
- Over the past 5 years, Benitec Biopharma's median Equity Average value was $13.2 million (recorded in 2021), while the average stood at $41.4 million.
- Per our database at Business Quant, Benitec Biopharma's Equity Average tumbled by 6638.01% in 2022 and then soared by 212155.36% in 2025.
- Quarter analysis of 5 years shows Benitec Biopharma's Equity Average stood at $13.2 million in 2021, then fell by 10.28% to $11.8 million in 2022, then surged by 60.03% to $18.9 million in 2023, then skyrocketed by 815.02% to $172.8 million in 2024, then surged by 73.33% to $299.6 million in 2025.
- Its Equity Average stands at $299.6 million for Q1 2025, versus $172.8 million for Q4 2024 and $55.7 million for Q3 2024.